COVID-19 rapid test 012G521

for antigensproteincoronavirus

The ulti med COVID-19 Antigen Saliva Test is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from 2019-nCoV in saliva specimens directly collected from individuals who are suspected of COVID-19 by their healthcare provider within the first 7 days of symptom onset. Results are for the identification of 2019-nCoV nucleocapsid protein antigen. PRINCIPLE The ulti med COVID-19 Antigen Saliva Test uses double-antibody sandwich to detect the antigen of novel coronavirus (2019-nCoV) in saliva samples. During detection, the gold labeled anti-2019-nCoV monoclonal antibody in the labeling pad binds to the 2019-nCoV antigen in the sample to form a complex, and the reaction complex moves forward along the nitrocellulose membrane under the action of chromatography. It is captured by the anti-2019-nCoV monoclonal antibody pre-coated on the detection zone (T) on the nitrocellulose membrane, and finally a red color reaction line is formed in the T zone. If the sample does not contain 2019-nCoV antigen, a red color reaction line cannot be formed in the T zone. If the sample does not contain 2019-nCoV antigens, a red reaction line cannot be formed in the T zone. Regardless of whether the sample to be tested contains 2019-nCoV antigens, a red reaction line will always form in the quality control area (C). Advantages Painless sampling due to saliva collection in the mouth Higher acceptance by test subjects Higher willingness for prophylactic, frequent testing Simplest test performance without handling, such as diluting and pipetting, with a possibly infectious sample